Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 35 articles: HTML format

Single Articles

September 2025
1. LIU JF, Colombo N, Oza AM, Frenel JS, et al
   ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.
   J Clin Oncol. 2025;43:2897-2907.
   PubMed     Abstract available
   
   
   July 2025
2. KONSTANTINOPOULOS PA, Kim JW, Freyer G, Lee JY, et al
   Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
   J Clin Oncol. 2025 Jul 23:JCO2500225. doi: 10.1200/JCO-25-00225.
   PubMed     Abstract available
   
   
   
3. SEWASTJANOW-SILVA M, Xiao L, Abdelhakeem A, Pabon CM, et al
   Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma.
   J Clin Oncol. 2025;43:2361-2371.
   PubMed     Abstract available
   
   
   
4. BANERJEE SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, et al
   Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
   J Clin Oncol. 2025 Jul 11:JCO2500112. doi: 10.1200/JCO-25-00112.
   PubMed     Abstract available
   
   
   June 2025
5. XIA L, Zhang K, Tang Y, Zhang G, et al
   Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.
   J Clin Oncol. 2025 Jun 25:JCO2402495. doi: 10.1200/JCO-24-02495.
   PubMed     Abstract available
   
   
   May 2025
6. SHAH M, Chen TY, Ison G, Fiero MH, et al
   Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
   J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834.
   PubMed     Abstract available
   
   
   March 2025
7. MATEI DE, Enserro DM, Randall ME, Mutch D, et al
   Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
   J Clin Oncol. 2025;43:1055-1060.
   PubMed     Abstract available
   
   
   
8. MARTH C, Moore RG, Bidzinski M, Pignata S, et al
   First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
   J Clin Oncol. 2025;43:1083-1100.
   PubMed     Abstract available
   
   
   February 2025
9. VAN DIJK D, Vermij L, Leon-Castillo A, Powell M, et al
   Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
   J Clin Oncol. 2025;43:443-452.
   PubMed     Abstract available
   
   
   January 2025
10. GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al
    Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589.
    PubMed     Abstract available
    
    
    
11. SLOMOVITZ BM, Cibula D, Lv W, Ortac F, et al
    Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
    J Clin Oncol. 2025;43:251-259.
    PubMed     Abstract available
    
    
    
12. CHEHADE R, Jerzak KJ, Tavanger F, Plotkin A, et al
    Advances in Vulvar Cancer Biology and Management.
    J Clin Oncol. 2025;43:89-100.
    PubMed     Abstract available
    
    
    December 2024
13. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
    Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
    J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
    PubMed     Abstract available
    
    
    November 2024
14. FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al
    Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
    J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686.
    PubMed     Abstract available
    
    
    October 2024
15. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
    Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
    J Clin Oncol. 2024;42:3537-3549.
    PubMed     Abstract available
    
    
    
16. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    PubMed     Abstract available
    
    
    
17. SANTIN AD, Corr BR, Spira A, Willmott L, et al
    Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
    J Clin Oncol. 2024;42:3421-3429.
    PubMed     Abstract available
    
    
    
18. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    PubMed     Abstract available
    
    
    
19. FERGUSON SE, Brotto LA, Kwon J, Samouelian V, et al
    Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.
    J Clin Oncol. 2024 Oct 1:JCO2400440. doi: 10.1200/JCO.24.00440.
    PubMed     Abstract available
    
    
    September 2024
20. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
    PubMed     Abstract available
    
    
    August 2024
21. BERCOW A, Del Carmen MG, Rauh-Hain JA, Melamed A, et al
    Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix.
    J Clin Oncol. 2024;42:2731-2735.
    PubMed     Abstract available
    
    
    
22. FELLON CM, Elsensohn AN, Kraus CN, Virgen CA, et al
    Vulvar Squamous Cell Carcinoma Guidelines May Benefit From Consideration of Tissue-Sparing Techniques as Treatment Options.
    J Clin Oncol. 2024;42:2723-2724.
    PubMed    
    
    
    
23. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    PubMed     Abstract available
    
    
    July 2024
24. KLOPP AH, Enserro D, Powell M, Randall M, et al
    Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
    J Clin Oncol. 2024;42:2425-2435.
    PubMed     Abstract available
    
    
    June 2024
25. HOROWITZ NS, Deng W, Peterson I, Mannel RS, et al
    Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
    J Clin Oncol. 2024;42:1914-1921.
    PubMed     Abstract available
    
    
    May 2024
26. RAMIREZ PT, Robledo KP, Frumovitz M, Pareja R, et al
    LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
    J Clin Oncol. 2024 May 29:JCO2302335. doi: 10.1200/JCO.23.02335.
    PubMed     Abstract available
    
    
    
27. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    PubMed     Abstract available
    
    
    
28. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    PubMed    
    
    
    April 2024
29. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    PubMed    
    
    
    
30. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    PubMed     Abstract available
    
    
    March 2024
31. CHARGARI C, Wasserman J, Gabro A, Canlobre G, et al
    Vulvar Carcinoma: Standard of Care and Perspectives.
    J Clin Oncol. 2024;42:961-972.
    PubMed     Abstract available
    
    
    
32. LUO PH, Mo DC, Wang HL, Liang XJ, et al
    Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
    J Clin Oncol. 2024 Mar 7:JCO2302479. doi: 10.1200/JCO.23.02479.
    PubMed    
    
    
    February 2024
33. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    PubMed     Abstract available
    
    
    
34. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed    
    
    
    January 2024
35. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.